BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1020 related articles for article (PubMed ID: 28514601)

  • 1. Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis.
    Wechsler ME; Akuthota P; Jayne D; Khoury P; Klion A; Langford CA; Merkel PA; Moosig F; Specks U; Cid MC; Luqmani R; Brown J; Mallett S; Philipson R; Yancey SW; Steinfeld J; Weller PF; Gleich GJ;
    N Engl J Med; 2017 May; 376(20):1921-1932. PubMed ID: 28514601
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Benralizumab versus Mepolizumab for Eosinophilic Granulomatosis with Polyangiitis.
    Wechsler ME; Nair P; Terrier B; Walz B; Bourdin A; Jayne DRW; Jackson DJ; Roufosse F; Börjesson Sjö L; Fan Y; Jison M; McCrae C; Necander S; Shavit A; Walton C; Merkel PA;
    N Engl J Med; 2024 Mar; 390(10):911-921. PubMed ID: 38393328
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of clinical benefit from treatment with mepolizumab for patients with eosinophilic granulomatosis with polyangiitis.
    Steinfeld J; Bradford ES; Brown J; Mallett S; Yancey SW; Akuthota P; Cid MC; Gleich GJ; Jayne D; Khoury P; Langford CA; Merkel PA; Moosig F; Specks U; Weller PF; Wechsler ME
    J Allergy Clin Immunol; 2019 Jun; 143(6):2170-2177. PubMed ID: 30578883
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-cytokine targeted therapies for ANCA-associated vasculitis.
    Bala MM; Malecka-Massalska TJ; Koperny M; Zajac JF; Jarczewski JD; Szczeklik W
    Cochrane Database Syst Rev; 2020 Sep; 9(9):CD008333. PubMed ID: 32990324
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mepolizumab for Eosinophilic Chronic Obstructive Pulmonary Disease.
    Pavord ID; Chanez P; Criner GJ; Kerstjens HAM; Korn S; Lugogo N; Martinot JB; Sagara H; Albers FC; Bradford ES; Harris SS; Mayer B; Rubin DB; Yancey SW; Sciurba FC
    N Engl J Med; 2017 Oct; 377(17):1613-1629. PubMed ID: 28893134
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial.
    Chupp GL; Bradford ES; Albers FC; Bratton DJ; Wang-Jairaj J; Nelsen LM; Trevor JL; Magnan A; Ten Brinke A
    Lancet Respir Med; 2017 May; 5(5):390-400. PubMed ID: 28395936
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacogenetic investigation of efficacy response to mepolizumab in eosinophilic granulomatosis with polyangiitis.
    Condreay LD; Parham LR; Qu XA; Steinfeld J; Wechsler ME; Raby BA; Yancey SW; Ghosh S
    Rheumatol Int; 2020 Aug; 40(8):1301-1307. PubMed ID: 32009195
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of conventional immunosuppressants in relapsing or refractory eosinophilic granulomatosis with polyangiitis: evidence from a Canadian single-centre cohort.
    Doubelt I; Pulenzas N; Carette S; Pagnoux C;
    Clin Exp Rheumatol; 2020; 38 Suppl 124(2):171-175. PubMed ID: 32167871
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adding Azathioprine to Remission-Induction Glucocorticoids for Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss), Microscopic Polyangiitis, or Polyarteritis Nodosa Without Poor Prognosis Factors: A Randomized, Controlled Trial.
    Puéchal X; Pagnoux C; Baron G; Quémeneur T; Néel A; Agard C; Lifermann F; Liozon E; Ruivard M; Godmer P; Limal N; Mékinian A; Papo T; Ruppert AM; Bourgarit A; Bienvenu B; Geffray L; Saraux JL; Diot E; Crestani B; Delbrel X; Sailler L; Cohen P; Le Guern V; Terrier B; Groh M; Le Jeunne C; Mouthon L; Ravaud P; Guillevin L;
    Arthritis Rheumatol; 2017 Nov; 69(11):2175-2186. PubMed ID: 28678392
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mepolizumab exerts crucial effects on glucocorticoid discontinuation in patients with eosinophilic granulomatosis with polyangiitis: a retrospective study of 27 cases at a single center in Japan.
    Yamane T; Hashiramoto A
    Arthritis Res Ther; 2023 Jun; 25(1):110. PubMed ID: 37365612
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies.
    Ortega HG; Yancey SW; Mayer B; Gunsoy NB; Keene ON; Bleecker ER; Brightling CE; Pavord ID
    Lancet Respir Med; 2016 Jul; 4(7):549-556. PubMed ID: 27177493
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mepolizumab: 240563, anti-IL-5 monoclonal antibody - GlaxoSmithKline, anti-interleukin-5 monoclonal antibody - GlaxoSmithKline, SB 240563.
    Drugs R D; 2008; 9(2):125-30. PubMed ID: 18298130
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma.
    Bel EH; Wenzel SE; Thompson PJ; Prazma CM; Keene ON; Yancey SW; Ortega HG; Pavord ID;
    N Engl J Med; 2014 Sep; 371(13):1189-97. PubMed ID: 25199060
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Pediatric Case of Relapsing Eosinophilic Granulomatosis with Polyangiitis Successfully Treated with Mepolizumab.
    Nara M; Saito M; Abe F; Komatsuda A; Wakui H; Takahashi N
    Intern Med; 2019 Dec; 58(24):3583-3587. PubMed ID: 31391393
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mepolizumab treatment in patients with severe eosinophilic asthma.
    Ortega HG; Liu MC; Pavord ID; Brusselle GG; FitzGerald JM; Chetta A; Humbert M; Katz LE; Keene ON; Yancey SW; Chanez P;
    N Engl J Med; 2014 Sep; 371(13):1198-207. PubMed ID: 25199059
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical Benefit of Mepolizumab in Eosinophilic Granulomatosis With Polyangiitis for Patients With and Without a Vasculitic Phenotype.
    Terrier B; Jayne DRW; Hellmich B; Bentley JH; Steinfeld J; Yancey SW; Kwon N; Akuthota P; Khoury P; Baylis L; Wechsler ME;
    ACR Open Rheumatol; 2023 Jul; 5(7):354-363. PubMed ID: 37312233
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial.
    Pavord ID; Korn S; Howarth P; Bleecker ER; Buhl R; Keene ON; Ortega H; Chanez P
    Lancet; 2012 Aug; 380(9842):651-9. PubMed ID: 22901886
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rituximab for the treatment of eosinophilic granulomatosis with polyangiitis (Churg-Strauss).
    Mohammad AJ; Hot A; Arndt F; Moosig F; Guerry MJ; Amudala N; Smith R; Sivasothy P; Guillevin L; Merkel PA; Jayne DR
    Ann Rheum Dis; 2016 Feb; 75(2):396-401. PubMed ID: 25467294
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical Features of Patients with Active Eosinophilic Granulomatosis with Polyangiitis Successfully Treated with Mepolizumab.
    Tsurikisawa N; Oshikata C; Watanabe M; Fukuda N; Yamaguchi T; Kiyohara H; Kaneko T
    Int Arch Allergy Immunol; 2021; 182(8):744-756. PubMed ID: 33887721
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Benralizumab for eosinophilic gastritis: a single-site, randomised, double-blind, placebo-controlled, phase 2 trial.
    Kliewer KL; Murray-Petzold C; Collins MH; Abonia JP; Bolton SM; DiTommaso LA; Martin LJ; Zhang X; Mukkada VA; Putnam PE; Kellner ES; Devonshire AL; Schwartz JT; Kunnathur VA; Rosenberg CE; Lyles JL; Shoda T; Klion AD; Rothenberg ME
    Lancet Gastroenterol Hepatol; 2023 Sep; 8(9):803-815. PubMed ID: 37336228
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 51.